[43, 44] have demonstrated that co‐administration of CD19 and CD20 or CD22 could overcome antigen escape and prolong the survival of B‐ALL or DLBCL patients compared to CD19 CAR‐T therapy. Here, CD22 is linked to acute lymphoblastic leukemia.